LRRK2 — LLMpedia

Contents

LRRK2 is a large multidomain protein implicated in familial and sporadic Parkinson's disease and studied across molecular biology, neurology, and pharmacology. First identified in genetic screens linked to familial parkinsonism, it has attracted attention from institutions such as National Institutes of Health, Broad Institute, and pharmaceutical companies including Pfizer and Biogen. Research on LRRK2 intersects with work on α-synuclein, Parkin (protein), and pathways examined by laboratories at University of Pennsylvania, Massachusetts Institute of Technology, and University College London.

Structure and Biochemical Properties

LRRK2 is a multidomain protein containing armadillo repeats, ankyrin repeats, leucine-rich repeats, a ROC (Ras of complex proteins) GTPase domain, a COR (C-terminal of ROC) domain, a serine/threonine kinase domain, and WD40 repeats, a domain architecture noted in structural studies at EMBL-EBI, Max Planck Institute, and Scripps Research. Biochemical characterization employs techniques from X-ray crystallography, cryo-electron microscopy, and mass spectrometry used by groups at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. Kinase activity is measured in assays developed by researchers at University of Cambridge and Stanford University, while GTPase activity assays were refined in studies at Harvard Medical School and Johns Hopkins University. The protein forms dimers and higher-order oligomers; oligomerization has been probed by teams at Karolinska Institutet and University of Oxford. Post-translational modifications characterized by investigators at Imperial College London include phosphorylation and ubiquitination, impacting biochemical stability studied in laboratories at Yale University.

Expression patterns for LRRK2 have been mapped in human brain regions including the substantia nigra, striatum, cortex, and cerebellum by consortia like the Human Brain Project and projects at Allen Institute for Brain Science. Peripheral expression is detected in cells of the immune system such as monocytes and macrophages studied by researchers at Pasteur Institute and Rothamsted Research. Subcellular localization studies by teams at MIT and UCL Great Ormond Street Institute of Child Health show LRRK2 at the cytosol, endosomes, lysosomes, mitochondria-associated membranes, and microtubules; localization is dynamic and influenced by interactions with proteins investigated at University of Toronto and McGill University. Imaging work from University of California, San Francisco and University of Sydney utilizes confocal microscopy, live-cell imaging, and super-resolution methods pioneered at Janelia Research Campus.

LRRK2 participates in vesicle trafficking, autophagy-lysosomal pathways, and cytoskeletal dynamics described in reviews from Mayo Clinic and experimental papers from Karolinska Institutet. It phosphorylates Rab GTPases and interacts with endosomal regulators studied at European Molecular Biology Laboratory and University of Zurich. Signaling cross-talk involves pathways linked to mTOR signaling, mitogen-activated protein kinase cascades analyzed by groups at Cold Spring Harbor Laboratory and Institut Pasteur, and immune signaling examined by investigators at National Institute of Allergy and Infectious Diseases. Functional assays exploring synaptic function were carried out at Columbia University and University of California, San Diego.

Missense variants such as G2019S and R1441C/G/H identified in linkage studies at McGill University and University of Rouen show strong association with familial Parkinson's disease. Population genetics and epidemiological analyses conducted by teams at Johns Hopkins Bloomberg School of Public Health and University of Oslo reveal variable penetrance across populations studied in cohorts at King's College London and National Taiwan University Hospital. Genome-wide association studies implicating LRRK2 regions have been reported by consortia including the International Parkinson Disease Genomics Consortium and work from Wellcome Trust Sanger Institute. Functional genomics and variant annotation tools developed at Broad Institute and European Bioinformatics Institute aid interpretation of pathogenicity.

Pathogenic variants increase kinase activity or alter GTPase function, leading to disrupted endolysosomal trafficking, impaired mitophagy, and neuroinflammation; these mechanisms were characterized in studies at University of Pennsylvania and UCL Institute of Neurology. Interactions with α-synuclein aggregation pathways were explored by labs at Rockefeller University and University of California, Los Angeles, while effects on mitochondrial dynamics were reported by researchers at Duke University and University of Barcelona. Cellular consequences include altered autophagic flux and cytoskeletal instability observed in neuronal cultures studied at Princeton University and Rutgers University.

Rodent models expressing human pathogenic variants have been developed at Harvard Medical School and are maintained in facilities affiliated with Jackson Laboratory and European Molecular Biology Laboratory. Nonhuman primate studies were conducted at centers such as Yerkes National Primate Research Center and Riken to assess neurodegeneration. Drosophila and C. elegans models used by groups at University of Oxford and University of Cambridge enabled rapid genetic screens, while zebrafish models at University of Edinburgh provided developmental insights. Behavioral phenotyping and pharmacodynamic studies were executed in collaborations with National Institute of Neurological Disorders and Stroke.

Small-molecule kinase inhibitors targeting the kinase domain have been developed by companies including AstraZeneca, GlaxoSmithKline, and Roche and tested in preclinical studies at Novartis Institutes for BioMedical Research. Clinical trials led by investigators at Massachusetts General Hospital and Mayo Clinic evaluate safety and target engagement. Strategies also include antisense oligonucleotides developed by teams at Ionis Pharmaceuticals and immune-modulatory approaches investigated at University of Pennsylvania. Biomarker research to monitor pharmacodynamic effects employs PET imaging centers such as Mayo Clinic and mass-spectrometry platforms at Scripps Research.